Lion Biotechnologies Inc. (LBIO) 8.3300 $LBIO
Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.
Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.
Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.
Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.
Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.
Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered
Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).
Lion Biotechnologies to Present at the LD MICRO Conference on December 3
Business Wire - Tue Nov 26, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.
Lion Biotechnologies Completes $23.3 Million Private Financing
Business Wire - Wed Nov 06, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) has completed a previously announced private financing with institutional and other accredited investors for gross proceeds of $23.3 million. After paying the placement agent fees and estimated offering expenses payable by the Company, Lion Biotechnologies received net proceeds of approximately $21.6 million.
Lion Biotechnologies to Raise Approximately $23 Million in Private Financing
Business Wire - Thu Oct 31, 7:00AM CDT
Lion Biotechnologies, Inc. (OTC Markets: LBIO) today announced that it has entered into definitive agreements with institutional and other accredited investors to raise approximately $23 million in a private financing. Subscribers have agreed to purchase units consisting of either (i) one share of common stock and a warrant to purchase a share of common stock, or (ii) one share of the newly authorized Series A Convertible Preferred Stock and a warrant to purchase the number of shares of common stock initially issuable upon the conversion of the preferred stock. The shares of common stock (and accompanying warrants) will be sold at $2.00 per share, and the shares of Series A Convertible Preferred Stock (and accompanying warrants) will be sold at $1,000 per share. The shares of Series A Convertible Preferred Stock will have a stated value of $1,000 per share and will initially be convertible into shares of common stock at a price of $2.00 per share (subject to customary adjustment for stock splits, reorganizations, and similar changes). Each warrant entitles the holder to acquire one share of common stock at a price of $2.50 for a period of five years from the closing.
Lion Biotechnologies to Present at the 4th Annual Cancer Immunotherapy Conference
GlobeNewswire - Mon Mar 24, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. The presentation is scheduled for Thursday, March 27, 2014, at 9:00 am Eastern Time.
Lion Biotechnologies to Present at the BioCentury Future Leaders Conference
GlobeNewswire - Fri Mar 21, 7:00AM CDT
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs), today announced that Chief Executive Officer Manish Singh, Ph.D., will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City. The presentation is scheduled for Friday, March 28, 2014, at 2:30 pm Eastern Time.
Lion Biotechnologies to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 1:00 p.m. Pacific in Salon 5. The conference is being held at The Ritz Carlton in Dana Point, California, from March 9-12, 2014.
Lion Biotechnologies Issues Letter to Shareholders
GlobeNewswire - Mon Feb 03, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO) announced that Chairman and CEO, Manish Singh, Ph.D., has issued the following letter to the shareholders.
Lion Biotechnologies' CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate's Immunotherapy Forum on January 27
Business Wire - Fri Jan 24, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled "Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies," the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.
Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report
M2 - Mon Jan 20, 9:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/fh839h/the_engineered) has announced the addition of the "Worldwide Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Report" report to their offering. This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. Benefits from the report: - Identify players in the field, from industry and academia; - Find out which TCR technologies are valued by Big Pharma and Biotech; - Understand the value of intracellular antigens targeted by the TCR; - Recognize the challenges of TCR-based therapeutics and their solutions; - Learn which TCR-based therapeutics are attractive for partnering; - Find out which TCR therapeutic approaches are not yet tapped. Key Topics Covered: 1. Executive Summary 2. Introduction 3. The T-Cell Receptor 4. TCR Fusion Proteins 5. TCR-Like (TCRL) Antibodies 6. TCR-Transfected T-Cells 7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells 8. Tumor-Infiltrating Lymphocytes (TILs) 9. Opportunity Analysis for TCR-based Products and Technologies 10. References 11. Corporate R&D Pipelines Companies Mentioned - Adaptimmune - Altor Bioscience - Immunocore - Lion Biotechnologies For more information visit http://www.researchandmarkets.com/research/fh...engineered
Lion Biotechnologies to Present at the Biotech Showcase on January 15
Business Wire - Mon Jan 13, 7:00AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will present at the Biotech Showcase on Wednesday, January 15, 2014, at 11:00 a.m. Pacific. The conference is being held at the Parc 55 Wyndham Union Square Hotel in San Francisco. Dr. Singh's presentation will be in Mission Room II.
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Business Wire - Thu Jan 09, 6:59AM CST
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced the appointment of James G. Bender, Ph.D., as Vice President, Product Development and Manufacturing. Dr. Bender has more than 25 years of clinical development experience, primarily focused on cancer therapies, including tumor-infiltrating lymphocytes (TILs).
Lion Biotechnologies to Present at the LD MICRO Conference on December 3
Business Wire - Tue Nov 26, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3, 2013, at 11:00 a.m. Pacific. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles.
Lion Biotechnologies Completes $23.3 Million Private Financing
Business Wire - Wed Nov 06, 7:00AM CST
Lion Biotechnologies, Inc. (OTC Markets: LBIO) has completed a previously announced private financing with institutional and other accredited investors for gross proceeds of $23.3 million. After paying the placement agent fees and estimated offering expenses payable by the Company, Lion Biotechnologies received net proceeds of approximately $21.6 million.
Lion Biotechnologies to Raise Approximately $23 Million in Private Financing
Business Wire - Thu Oct 31, 7:00AM CDT
Lion Biotechnologies, Inc. (OTC Markets: LBIO) today announced that it has entered into definitive agreements with institutional and other accredited investors to raise approximately $23 million in a private financing. Subscribers have agreed to purchase units consisting of either (i) one share of common stock and a warrant to purchase a share of common stock, or (ii) one share of the newly authorized Series A Convertible Preferred Stock and a warrant to purchase the number of shares of common stock initially issuable upon the conversion of the preferred stock. The shares of common stock (and accompanying warrants) will be sold at $2.00 per share, and the shares of Series A Convertible Preferred Stock (and accompanying warrants) will be sold at $1,000 per share. The shares of Series A Convertible Preferred Stock will have a stated value of $1,000 per share and will initially be convertible into shares of common stock at a price of $2.00 per share (subject to customary adjustment for stock splits, reorganizations, and similar changes). Each warrant entitles the holder to acquire one share of common stock at a price of $2.50 for a period of five years from the closing.
